Previous 10 | Next 10 |
Global Blood Therapeutics (NASDAQ:GBT) announced that an expert panel of the European Medicines Agency (EMA) recommended the approval for the company’s oral drug Oxbryta (voxelotor) for hemolytic anemia due to sickle cell disease (SCD). EMA’s Medicinal Products for Human Use (CH...
European Commission decision on marketing authorization anticipated first quarter of 2022 Oxbryta would be the first oral treatment available in Europe to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease HbS pol...
Shares of Global Blood Therapeutics (GBT +8.2%) are trading higher today after the company priced an upsized $300M convertible senior notes offering. Net proceeds will be used to pay the cost of the capped call transactions, for development and commercialization of Oxbryta, a treatment for si...
Global Blood Therapeutics (NASDAQ:GBT) has priced $300M of its 1.875% Convertible Senior Notes due 2028 in a private offering, upsized from previous offering size of $250M. Initial purchasers are granted an option to purchase up to an additional $45M of notes. Initial conversion rate is 31.49...
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the pricing of $300.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the “notes”) in a private offering (the ...
Global Blood Therapeutics (NASDAQ: GBT) shares took a big dive on Tuesday, sliding to close more than 14% lower. Investors weren't happy that the company is launching a big new round of financing. Tuesday morning, Global Blood Therapeutics announced that it is floating a $250 mi...
Adagio Therapeutics (NASDAQ:ADGI) -67% after Omicron led to 300-fold reduction in neutralizing effect in COVID-19 therapy. Aptose Biosciences (NASDAQ:APTO) -32% following ASH data on acute myeloid leukemia candidate. SeaChange International (NASDAQ:SEAC) -22%. Mesoblast (N...
Global Blood Therapeutics (NASDAQ:GBT) intends to offer $250.0M aggregate principal amount of its convertible senior notes due 2028 in a private offering. Initial purchasers will be granted a 13-day option to purchase up to an additional $37.5M principal amount of Notes. There can be no ...
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it intends to offer $250.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the “notes”) in a private offerin...
Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol Canada NewsWire Companies will collaborate on manufacturing and research and development for future indications, and will commercialize Gadopiclenol independently under sepa...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...